<code id='8DD6844B2E'></code><style id='8DD6844B2E'></style>
    • <acronym id='8DD6844B2E'></acronym>
      <center id='8DD6844B2E'><center id='8DD6844B2E'><tfoot id='8DD6844B2E'></tfoot></center><abbr id='8DD6844B2E'><dir id='8DD6844B2E'><tfoot id='8DD6844B2E'></tfoot><noframes id='8DD6844B2E'>

    • <optgroup id='8DD6844B2E'><strike id='8DD6844B2E'><sup id='8DD6844B2E'></sup></strike><code id='8DD6844B2E'></code></optgroup>
        1. <b id='8DD6844B2E'><label id='8DD6844B2E'><select id='8DD6844B2E'><dt id='8DD6844B2E'><span id='8DD6844B2E'></span></dt></select></label></b><u id='8DD6844B2E'></u>
          <i id='8DD6844B2E'><strike id='8DD6844B2E'><tt id='8DD6844B2E'><pre id='8DD6844B2E'></pre></tt></strike></i>

          explore

          explore

          author:explore    Page View:7557
          Three boxes of Wegovy stands in a line — coverage from STAT
          Steffen Trumpf/picture alliance/Getty Images

          WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT.

          Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law, the Food and Drug Administration’s move could give doctors an avenue to prescribe the medications to some Medicare patients.

          advertisement

          Wegovy’s new label indicates that the drug can be used to reduce the risk of major heart complications for people who are overweight or obese and have existing heart disease, Novo said in a statement Friday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          Why health care costs have stayed mostly flat since 2010
          Why health care costs have stayed mostly flat since 2010

          AdobeAllAmericansareworriedaboutinflation.Thepricesforhousing,clothesandfoodatthesupermarketareeyepo

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Albert Bourla of Pfizer: worst biopharma CEO of 2023

          HyacinthEmpinado/STATPfizeristhisyear’santi-EliLilly.IfDavidRicksisthebestbiopharmaCEOof2023,thenPfi